Autocallable Multi Barrier Reverse Convertible

Symbol: KZEHDU
ISIN: CH1390260128
Issuer:
UBS
Trade

Chart

    
    

SIX Structured Products trading

SIX Structured Products Bid Ask Notation
Please note that data is only available after start of trading.
Trading hours for this product: 9:15 – 17:15

Performance

Closing prev. day 47.80
Diff. absolute / % 0.80 +1.40%

Determined prices

Last Price 47.70 Volume 20,000
Time 10:00:02 Date 27/11/2025

More Product Information

Core Data

Name Autocallable Multi Barrier Reverse Convertible
ISIN CH1390260128
Valor 139026012
Symbol KZEHDU
Quotation in percent Yes
Coupon p.a. 8.00%
Coupon Premium 7.65%
Coupon Yield 0.35%
Type Multi Barrier Reverse Convertibles
SVSP Code 1230
Barrier reached Yes (Novo Nordisk AS (B) - 04/04/2025)
COSI Product No
Exercise type American
Currency Swiss Franc
First Trading Date 20/11/2024
Date of maturity 20/11/2026
Last trading day 13/11/2026
Settlement Type Cash payout
IRS 871m Potentially in scope for combined transactions
Currency safeguarded Yes
Pricing Clean
Issuer UBS

Key data

Ask Price (basis for calculation) 48.3000
Maximum yield 120.70%
Maximum yield p.a. 131.12%
Sideways yield -1.40%
Sideways yield p.a. -1.52%

market maker quality Date: 17/12/2025

Average Spread 2.10%
Last Best Bid Price 47.45 %
Last Best Ask Price 48.45 %
Last Best Bid Volume 100,000
Last Best Ask Volume 100,000
Average Buy Volume 100,000
Average Sell Volume 100,000
Average Buy Value 47,159 CHF
Average Sell Value 48,159 CHF
Spreads Availability Ratio 99.95%
Quote Availability 99.95%

Underlyings

Name Eli Lilly & Co. Novo Nordisk AS (B)
ISIN US5324571083 DK0062498333
Price 790.00 CHF 41.18 EUR
Date 11/12/25 15:43 19/12/25 23:00
Cap 811.81 USD 756.00 DKK
Distance to Cap 253.9 -451.7
Distance to Cap in % 23.82% -148.44%
Is Cap Level reached No No
Barrier 487.086 USD 453.60 DKK
Distance to Barrier 578.624 3.25001
Distance to Barrier in % 54.29% 0.71%
Is Barrier reached No Yes

Please wait...
The data push was deactivated due to a timeout. Please click "Refresh page" to continue.